Institutional Sentiment Positive Towards Cellect Biotechnology Ltd. (APOP)

Cellect Biotechnology Ltd. (NASDAQ:APOP) reached -17.86% versus a 1-year low price of $1.4. The stock was last seen -49.78% lower, reaching at $1.15 on 02/08/2019. At recent session, the prices were hovering between $1.14 and $1.26. This company shares are 943.48% off its target price of $12 and the current market capitalization stands at $7.5M. The recent change has given its price a -58.72% deficit over SMA 50 and -85.82% deficit over its 52-week high. The stock witnessed -61.28% declines, -76.48% declines and -78.86% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found APOP’s volatility during a week at 48.39% and during a month it has been found around 19.39%.

The decline came after the company announced the pricing of an underwritten public offering of 1,889,000 units, with each unit consisting of one American Depositary Share (ADS) and a warrant to purchase one ADS as well as 2,444,800 pre-funded units, with each pre-funded unit consisting of a pre-funded warrant to purchase one ADS and a warrant to purchase one ADS.

Each unit will be sold at $1.50 per unit and each pre-funded unit will be sold at $1.49 per pre-funded unit. The pre-funded warrants will be exercisable at any time after the date of issuance upon payment of the exercise price of $0.01 per ADS. The warrants will have a term of five years, be exercisable immediately and have an exercise price of $1.50 per ADS. The ADSs or the pre-funded warrants and the accompanying warrants included in the units or pre-funded units can only be purchased together in this offering, but will be issued separately and will be immediately separable upon issuance. Cellect has granted the underwriters a 45-day option to purchase an additional 650,070 ADSs and/or additional warrants to purchase 650,070 ADSs.

The offering is expected to close on or about February 12, 2019, subject to customary closing conditions. Cellect intends to use the net proceeds from the offering for working capital and general corporate purposes, including research and development, clinical trials and general and administrative expenses.

Cellect Biotechnology Ltd. 13F Filings

At the end of September reporting period, institutional holders increased their position in Cellect Biotechnology Ltd. (NASDAQ:APOP) by some shares, 4 decreased positions by 46,304 and 1 held positions by 108,490. That puts total institutional holdings at 154,794 shares, according to SEC filings. The stock grabbed new institutional investments totaling shares while 1 institutional investors sold out their entire positions totaling 1,520 shares.

Earlier this month, APOP announced a collaboration with Washington University, a leading academic institution based in St. Louis, MO, aimed at determining the safety and tolerability in a U.S. Phase I/II study using ApoGraft™ for bone marrow transplantations. The collaboration is led by Dr. John DiPersio, Director of the Center for Gene and Cellular Immunotherapy at Washington University School of Medicine and President of the American Society for Blood and Marrow Transplantation, and Dr. Mark Schroeder, an expert in bone marrow transplantation in the Division of Oncology at Washington University School of Medicine.

This will be the first clinical trial in the U.S. using the Company’s ApoGraft stem cell selection technology, which is designed to prevent acute graft-versus-host disease following bone marrow transplantation. Previously, the Company has reported positive safety and tolerability data from an ongoing trial that is being performed outside the U.S., and expects to report additional interim results during the first half of 2019. This open label clinical trial of twelve patients, expected to complete recruitment during the second quarter of 2019, is designed to evaluate the safety and tolerability of the ApoGraft™ process in patients with hematological malignancies who are undergoing an allogeneic hematopoietic stem cell transplantation (HSCT). The primary endpoint of the study is overall incidence, frequency and severity of adverse events potentially related to ApoGraft™ at 180 days from transplantation.